The study develops a novel bone cement that enhances bioactivity and mechanical strength in orthopedic applications, suggesting improved treatment outcomes.
Conventional calcium sulfate bone cements suffer from rapid degradation, poor anti-washout property, and inadequate bioactivity. To overcome these limitations, we developed an injectable bone cement based on a novel ternary synergistic system of Sr-doped alginate-phosphate (SA/Sr/PO₄³⁻) and hydrothermally synthesized α-calcium sulfate hemihydrate (α-CSH). This design leverages the rapid physical crosslinking between Ca²⁺ from α-CSH and the guluronic acid/mannuronic acid blocks of sodium alginate, resulting in a reinforced network with enhanced initial anti-washout property and a wet compressive strength of 2-12 MPa. Simultaneously, the alginate matrix induces the in situ mineralization of Ca²⁺ and PO₄³⁻ ions, forming a calcium-deficient hydroxyapatite (CDHA) precursor that decelerates the degradation rate (18% in PBS over 60 days) to match new bone formation. In addition, strontium ions (Sr²⁺) sustainably released from the material promote in vitro osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs). This work presents a novel composite cement that successfully integrates injectability, robust mechanical properties, controllable degradation, and osteoinductive capability.
No takes yet. Share an insight, caveat, or question.
Tang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: